Caricamento...
ESR1 Mutations in Breast Cancer
The acquisition of ligand-independent ESR1 mutations during aromatase inhibitor (AI) therapy in metastatic estrogen receptor (ER)-positive breast cancer is a common mechanism of hormonal therapy resistance. Preclinical and clinical studies have demonstrated that ESR1 mutations can pre-exist in prima...
Salvato in:
| Pubblicato in: | Cancer |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6788940/ https://ncbi.nlm.nih.gov/pubmed/31318440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32345 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|